In this article
New Early Detection Technology for Liver Cancer
A medical technology company focused on developing innovative technologies for early diagnosis of cancer, today announced new research results. A clinical study of liver cancer has demonstrated the great potential of LAM’s new DNA methylation-based biomarker to detect hepatocellular carcinoma (HCC) The detection sensitivity is 95% and the specificity is 97.5%.
In this study, stock samples of 130 subjects were collected, including: 60 subjects diagnosed with hepatocellular carcinoma (stage I to IV), 30 subjects without liver disease, 10 Subjects diagnosed with benign liver disease and 30 subjects diagnosed with breast cancer, colorectal cancer or lung cancer. DNA was extracted from the sample, the DNA was transformed with bisulfite, and DNA methylation was quantified using the IvyGene platform. After completing the data collection and analysis of all samples, blind the samples to calculate the test performance.
High Sensitivity and Specificity Study Results
A total of 57 of the 60 samples taken from patients with hepatocellular carcinoma were correctly identified, with an overall calculated sensitivity of 95%. The sensitivity difference between detecting stage I and stage IV hepatocellular carcinoma was small (range 89% to 100%). Of the samples taken from cancer patients other than liver cancer, 90% of breast cancer samples, 80% of colorectal cancer samples, and 90% of lung cancer samples were correctly identified as non-liver cancer, and the total calculated specificity was 87%.
For details on best options for liver cancer treatment, do call us at +91 96 1588 1588 or write to [email protected].
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
About Dr. Nishant Mittal
Dr. Nishant Mittal is a highly accomplished researcher with over 13 years of experience in the fields of cardiovascular biology and cancer research. Significant contributions to stem cell biology, developmental biology, and innovative research techniques mark his career. Research Highlights Dr. Mittal's research has focused on several key areas: 1) Cardio…
✓ Reviewed for medical accuracy by the CancerFax review panel.
Medical Disclaimer
This article is for educational purposes only and should not replace medical advice, diagnosis, or treatment from a qualified oncology specialist. Every patient's case is different. Treatment decisions should always be made after a review of complete medical records by the treating medical team.
Treatment availability, eligibility, timelines, and access can change. Any clinical trial participation depends on detailed review and approval by the trial hospital or investigator.